Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 7CNS 6Genitourinary 3NET 2Head & Neck 2Tumor-Agnostic 1Gastrointestinal 1Breast 1

Conditions

von Hippel-Lindau Disease 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Multiple Endocrine Neoplasia Type 1 1

Interventions

Oxaliplatin 152Fluorouracil 138Gemcitabine 118Bevacizumab 117Leucovorin 107Specimen Handling 105Capecitabine 96pembrolizumab 91Magnetic Resonance Spectroscopy 83Nivolumab 79Cisplatin 79Irinotecan 72durvalumab 64Cetuximab 62Biopsy 61Paclitaxel 60130-nm albumin-bound paclitaxel 60atezolizumab 46Radiotherapy 46Albumin-Bound Paclitaxel 37Taxes 36Carboplatin 36Folfox protocol 35Drug Therapy 32Cyclophosphamide 30lenvatinib 29dehydroftorafur 29tislelizumab 27sintilimab 27Radiation 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
gallium Ga 68 dotatate × Gastrointestinal × 90 days × Clear all
NCT04074135 2026-04-20

Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
740 enrolled
EndocrineGastrointestinalNET

von Hippel-Lindau Disease, Pancreatic Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡